Total Funding
2
54
Total FundingPre-Seed raised
Growth Score 2 in past quarter
-7 pts
Heat Score 54 in past quarter
-23 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
152743
Pharmaceutical Development, 505b2, New Drug Delivery Technology
- Luke Wang: Co-Founder and COO
- Jianwei Yu: Co-founder, President and CEO
About the Company
SPES is a specialty pharmaceutical company focusing on patient medical needs through innovative science and technologies. The company is developing twelve 505(b)(2) products based on three innovative platforms. The candidate products are targeting therapeutic areas including oncology, antiemetic, CNS, and pain management to provide patients with
safer and more efficient treatment options.